BIOA

Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity at week 12 Topline results expected in the second half of 2027 Beyond DME, results will inform development strategy in other NLRP3-driven retinal diseases, including geographic atrophy EMERYVILLE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge" or the "Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the first particip

EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: Citi Biopharma Back to School Conference (New York, September 9–10, 2026): Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Wednesday, September 9 at 11:20–11:55 AM EDT. Kristen Fortney and Dov Goldstein, MD, CFO, will participate in one-on-one meetings. To access the live webcast of the pr

STOCKHOLM, Aug. 31, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 20,200 Class B shares during August for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 20,200 stock options of series 2019/2028. As of August 31, 2026, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,744,685 shares, of which 74,344,689 listed Class B shares and 14,399,996 unlisted Class A shares. The A share has ten votes per share and the B share has one vote per share. The total number of votes

SCHEDULE 13G/A - BioAge Labs, Inc. (0001709941) (Subject)

10-Q - BioAge Labs, Inc. (0001709941) (Filer)

8-K - BioAge Labs, Inc. (0001709941) (Filer)

First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026 QUELL-DME, Phase 1b/2a proof-of-concept trial of BGE-102 in diabetic macular edema, planned to initiate in mid-2026, with data anticipated in mid-2027; results expected to support development across inflammation-driven retinal diseases Hosted R&D Day focused on NLRP3 inhibition, featuring Phase 1 data for BGE-102 EMERYVILLE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge" or "the Company"), a clinical-stage biopharmaceutical company developing therapeut

STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study showing that nearly 83% of patients with early Alzheimer's disease (AD) enrolled in the study remained stable (75.9%) or improved (6.6%) while receiving Leqembi over an average of 17 months. The results were consistent across sex, race, ethnicity and APOE genotype. The data were presented during the session "Developing Topics Session #3-33-DEV-A: Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings" at the Al

4 - BioAge Labs, Inc. (0001709941) (Issuer)

Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors Primary endpoint is percent change in high-sensitivity C-reactive protein (hsCRP); trial designed to support optimal dose selection for Phase 3 Trial builds on previously reported Phase 1 results in which BGE-102 achieved potential best-in-class hsCRP reductions and was well tolerated across all dose levels Topline data anticipated in the second half of 2026 EMERYVILLE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge" or the "Company"), a clinic

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

8-K - BioAge Labs, Inc. (0001709941) (Filer)

Roth Capital initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $36.00

EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: • Jefferies Global Healthcare Conference (New York, June 3–4, 2026): Dov Goldstein, MD, CFO, and BJ Sullivan, PhD, Chief Strategy Officer, are scheduled to participate in a fireside chat on Thursday, June 4 at 3:45–4:15 PM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here. • Gol

Cell therapies and precision biologics are driving new opportunities across longevity, cognitive health, and neurological disease sectorsNEW YORK, May 20, 2026 /PRNewswire/ -- Market News Updates News Commentary - Cell-based therapies are quickly becoming one of the most talked-about areas in healthcare as researchers move beyond traditional drugs and focus on repairing and regenerating the body at the cellular level. Instead of only treating symptoms, scientists are now exploring ways to potentially reverse damage tied to aging and chronic disease. In the anti-aging space, stem cells, regenerative biologics, and senolytic therapies are being studied for their potential to restore tissue fun

SCHEDULE 13G/A - BioAge Labs, Inc. (0001709941) (Subject)

Equity Insider News CommentaryIssued on behalf of Avaí Bio, Inc.Joint venture with Austrianova advances the production of cells that produce the longevity protein α-Klotho from encapsulated cells; latest data to be presented at the Second Annual Klotho ConferenceNEW YORK, May 14, 2026 /CNW/ -- Longevity and anti-aging therapeutics have moved decisively from frontier science to organized commercial development through the first half of 2026. Industry data show approximately $3.74 billion of disclosed longevity-biotech financing in Q1 2026 across 49 deals — a 56% increase in capital deployed over Q1 2025 — and the broader longevity biotech market has been forecast to reach approximately US$29.

BTIG Research initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $40.00

8-K - BioAge Labs, Inc. (0001709941) (Filer)

10-Q - BioAge Labs, Inc. (0001709941) (Filer)